KIT and acute myeloid leukemia: Median OS was not significantly different (16.7 vs. 26.4 months, P = 0.4) between KIT D816mut/CBFneg SM-AML and KIT D816mut/CBFneg AMLdatabases patients who received intensive chemotherapy (Fig. 3a, b).